title: Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
abstract: The chemopreventive effects of Ibuprofen on the development and growth of 7,12-dimethylbenz(a)anthracene (DMBA) induced rat mammary tumors were examined. A well known breast cancer chemopreventive retinoid, N-(4-hydroxyphenyl) retinamide (4-HPR) was also included in this study for comparison. At 7 days prior to receiving a single intragastric dose of 15 mg DMBA, rats were fed a control chow diet, as well as diets containing either 1000 mg/kg diet of Ibuprofen or 1.5 mmol/kg diet of 4-HPR. Ibuprofen and 4-HPR markedly increased tumor latency. At 112 days post DMBA intubation, tumor incidence was 86% in control rats as compared to 74% and 62% in rats receiving Ibuprofen, and 4-HPR diets respectively (p < 0.05). Ibuprofen and 4-HPR reduced tumor burden and tumor volume almost to the same extent. The control rats had an average of 2.26 tumors/rat compared to 1.42 and 1.46 tumors/rat in the Ibuprofen or 4-HPR groups respectively (p < 0.05). Similarly, average tumor volume was 3.25 cm3 in the control rats compared to 0.86 cm3 and 0.83 cm3 in rats receiving Ibuprofen and 4-HPR diets respectively (p < 0.05). These results suggest that Ibuprofen may have potential in the chemoprevention and treatment of breast cancer.
authors.affiliation: Department of Surgery, College of Medicine and Public Health, Ohio State University, Columbus 43210, USA.
authors.forename: G A
authors.initials: GA
authors.lastname: Alshafie
authors.forename: R E
authors.initials: RE
authors.lastname: Harris
authors.forename: F M
authors.initials: FM
authors.lastname: Robertson
authors.forename: M L
authors.initials: ML
authors.lastname: Parrett
authors.forename: M
authors.initials: M
authors.lastname: Ross
authors.forename: H
authors.initials: H
authors.lastname: Abou-Issa
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D005260:Female; D017313:Fenretinide / Q000494:pharmacology*; D007052:Ibuprofen / Q000494:pharmacology*; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D016588:Anticarcinogenic Agents; D017313:Fenretinide; D007052:Ibuprofen